Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2021

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities approximately consist of the following:


		2021			2020

Incentive compensation		$	504,000		$	850,000
Accounts payable			1,415,000			1,429,000
Clinical project costs			1,881,000			787,000
Professional fees			54,000			221,000
Other			1,000			156,000
		$	3,855,000		$	3,443,000